Literature DB >> 15750116

Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.

Jan Weber1, Bikram Chakraborty, Jitka Weberova, Michael D Miller, Miguel E Quiñones-Mateu.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) resistance mutation K65R confers intermediate levels of resistance to several RT inhibitors, including a three- to fourfold reduction of tenofovir susceptibility. Here, we have used for the first time primary HIV-1 isolates from individuals who developed the K65R mutation while enrolled in a clinical trial of tenofovir to analyze the impact of this mutation on HIV-1 replicative fitness. A marked impairment in replicative fitness was observed in association with the selection of viruses carrying the K65R mutation in all patients. The mean replicative fitness among these viruses was 20% relative to the corresponding baseline wild-type virus, ranging from 10 to 32% depending on the accompanying RT mutations. These results support a reduction in in vivo replication for K65R mutant viruses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15750116      PMCID: PMC1081293          DOI: 10.1128/JCM.43.3.1395-1400.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

1.  Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations.

Authors:  Jérôme Deval; Kirsten L White; Michael D Miller; Neil T Parkin; Jérôme Courcambeck; Philippe Halfon; Boulbaba Selmi; Joëlle Boretto; Bruno Canard
Journal:  J Biol Chem       Date:  2003-10-09       Impact factor: 5.157

2.  Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.

Authors:  V S Torre; A J Marozsan; J L Albright; K R Collins; O Hartley; R E Offord; M E Quiñones-Mateu; E J Arts
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing.

Authors:  J Martinez-Picado; L Sutton; M P De Pasquale; A V Savara; R T D'Aquila
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

4.  pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D.

Authors:  M Cornelissen; R van den Burg; F Zorgdrager; V Lukashov; J Goudsmit
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

5.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Authors:  Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng
Journal:  JAMA       Date:  2004-07-14       Impact factor: 56.272

Review 6.  Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.

Authors:  Joel E Gallant; Peter Z Gerondelis; Mark A Wainberg; Nancy S Shulman; Richard H Haubrich; Marty St Clair; Ernest R Lanier; Nicholas S Hellmann; Douglas D Richman
Journal:  Antivir Ther       Date:  2003-12

7.  The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters.

Authors:  Koen K A Van Rompay; Raman P Singh; Laurie L Brignolo; Jonathan R Lawson; Kimberli A Schmidt; Bapi Pahar; Don R Canfield; Ross P Tarara; Donald L Sodora; Norbert Bischofberger; Marta L Marthas
Journal:  J Acquir Immune Defic Syndr       Date:  2004-08-01       Impact factor: 3.731

8.  Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.

Authors:  Z Gu; Q Gao; H Fang; H Salomon; M A Parniak; E Goldberg; J Cameron; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  D Zhang; A M Caliendo; J J Eron; K M DeVore; J C Kaplan; M S Hirsch; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

10.  In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.

Authors:  M A Wainberg; M D Miller; Y Quan; H Salomon; A S Mulato; P D Lamy; N A Margot; K E Anton; J M Cherrington
Journal:  Antivir Ther       Date:  1999
View more
  32 in total

1.  K65R and K65A substitutions in HIV-1 reverse transcriptase enhance polymerase fidelity by decreasing both dNTP misinsertion and mispaired primer extension efficiencies.

Authors:  Scott J Garforth; Robert A Domaoal; Chisanga Lwatula; Mark J Landau; Amanda J Meyer; Karen S Anderson; Vinayaka R Prasad
Journal:  J Mol Biol       Date:  2010-06-09       Impact factor: 5.469

2.  Impaired replication capacity of acute/early viruses in persons who become HIV controllers.

Authors:  Toshiyuki Miura; Zabrina L Brumme; Mark A Brockman; Pamela Rosato; Jennifer Sela; Chanson J Brumme; Florencia Pereyra; Daniel E Kaufmann; Alicja Trocha; Brian L Block; Eric S Daar; Elizabeth Connick; Heiko Jessen; Anthony D Kelleher; Eric Rosenberg; Martin Markowitz; Kim Schafer; Florin Vaida; Aikichi Iwamoto; Susan Little; Bruce D Walker
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

3.  Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice.

Authors:  Graciela Andrei; Don B Gammon; Pierre Fiten; Erik De Clercq; Ghislain Opdenakker; Robert Snoeck; David H Evans
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 4.  Adherence-resistance relationships to combination HIV antiretroviral therapy.

Authors:  David R Bangsberg; Deanna L Kroetz; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2007-05       Impact factor: 5.071

Review 5.  The high cost of fidelity.

Authors:  Sarah B Lloyd; Stephen J Kent; Wendy R Winnall
Journal:  AIDS Res Hum Retroviruses       Date:  2014-01       Impact factor: 2.205

6.  International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase.

Authors:  Philip M Grant; Jonathan Taylor; Andrew B Nevins; Vincent Calvez; Anne-Geneviève Marcelin; Marc Wirden; Andrew R Zolopa
Journal:  Antimicrob Agents Chemother       Date:  2010-02-01       Impact factor: 5.191

7.  The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.

Authors:  Urvi M Parikh; Lee Bacheler; Dianna Koontz; John W Mellors
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 8.  Quasispecies and virus.

Authors:  Esteban Domingo; Celia Perales
Journal:  Eur Biophys J       Date:  2018-02-03       Impact factor: 1.733

9.  Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance.

Authors:  George K Hightower; Scott L Letendre; Mariana Cherner; Sarah A Gibson; Ronald J Ellis; Tanya J Wolfson; Anthony C Gamst; Caroline C Ignacio; Robert K Heaton; Igor Grant; Douglas D Richman; Davey M Smith
Journal:  Virology       Date:  2009-09-16       Impact factor: 3.616

10.  Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course.

Authors:  Nicole Prada; Brandi Davis; Patrick Jean-Pierre; Matthew La Roche; Fuh-Mei Duh; Mary Carrington; Michael Poles; Saurabh Mehandru; Hiroshi Mohri; Martin Markowitz
Journal:  J Acquir Immune Defic Syndr       Date:  2008-10-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.